Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Pushing Therapeutic Boundaries in CLL

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

 

Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors

Recorded on Tuesday, August 24, 2021 

Healthcare providers can receive CME credit for important CLL topics with speakers Drs. Matthew Davids and Susan O’Brien.

Novel targeted therapies such as BTK inhibitors are bringing hope to (chronic lymphocytic leukemia) CLL patients. Yet tailored therapies can make determining the right options complex. Join expert hematologists and oncologists to review recommended therapy selection strategies, discuss key treatment combinations and evaluate BTK inhibitors for managing relapsed or refractory disease. You can earn AMA PRA Category 1 Credit™.

Recorded Sessions

Emerging Combinations for Newly Diagnosed CLL

High‐Risk Relapsed/Refractory (R/R) CLL